Ulrike Lorch

St George's University Of London
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study.

Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: October 09, 2025

The safety of early phase clinical trials: Bridging the gap between governance and practice.

The safety of early phase clinical trials: Bridging the gap between governance and practice.

Journal: British journal of clinical pharmacology

Published: May 03, 2024

No Measurable Transfer of Oxytocin-Receptor Agonist Merotocin Detected in Human Breast Milk.

No Measurable Transfer of Oxytocin-Receptor Agonist Merotocin Detected in Human Breast Milk.

Journal: Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine

Published: March 26, 2024

A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants.

A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: March 12, 2024

Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled Trials.

Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled Trials.

Journal: Cureus

Published: August 27, 2023

Randomized, placebo-controlled, double-blind phase I trial of co-administered pyronaridine and piperaquine in healthy adults of sub-Saharan origin.

Randomized, placebo-controlled, double-blind phase I trial of co-administered pyronaridine and piperaquine in healthy adults of sub-Saharan origin.

Journal: Clinical and translational science

Published: August 24, 2023

The Reliability of Auto-Injectors in Clinical Use: A Systematic Review.

The Reliability of Auto-Injectors in Clinical Use: A Systematic Review.

Journal: Cureus

Published: July 09, 2023

Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges.

Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges.

Journal: Frontiers in pharmacology

Published: May 09, 2023

Both osmolality-dependent and independent mechanisms are associated with acute hyperglycemia-induced cardiovascular adverse reactions: Analysis of the mutual interactions leading to cardiovascular phenotypes in dogs.

Both osmolality-dependent and independent mechanisms are associated with acute hyperglycemia-induced cardiovascular adverse reactions: Analysis of the mutual interactions leading to cardiovascular phenotypes in dogs.

Journal: The Journal of toxicological sciences

Published: March 01, 2023

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation.

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation.

Journal: Frontiers in immunology

Published: October 18, 2022

Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study.

Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study.

Journal: Diagnostic microbiology and infectious disease

Published: July 14, 2021

Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.

Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.

Journal: Clinical pharmacology and therapeutics

Published: May 10, 2021

Showing 1-12 of 42

Last Updated: 09/26/2026